As the brain’s fluid drainage systems become sluggish with age, troublemakers such as amyloid and tau aggregates start to build up. To flush out disease-causing detritus, neurosurgeons in China have ...
As the strongest risk factor for Alzheimer’s disease, ApoE4 has a bad reputation, and rightly so. Yet shade thrown on ApoE4 may be obscuring the inconvenient truth that ApoE3 isn’t so innocent, either ...
R47H is a rare variant in TREM2 that triples the risk of Alzheimer’s disease in heterozygous carriers of this variant. In order to study the effects of R47H TREM2 in the context of amyloidosis, Trem2 ...
Progranulin is an obvious target for a frontotemporal dementia therapy, as up to 15 percent of cases arise from loss-of-function mutations in its gene, GRN. In a study published January 7 in Science ...
This approach uses mesenchymal stem cells isolated from a patient’s own fat tissue to treat neurodegenerative diseases. The stem cells are supposed to assist in repair of damaged tissue and ...
What makes synapses disappear with age? In the January 21 Nature, scientists led by Tony Wyss-Coray at Stanford University School of Medicine, California, report that sluggish turnover of synaptic ...
The App SAA mouse joins a list of knock-in models that carry a humanized Aβ sequence within the murine App gene (App knock-in (humanized Aβ), APP NL-F Knock-in, APP NL-G-F Knock-in). As in the latter ...
Professional Information Assistant ProfessorHarvard Medical School, Massachusetts General Hospital http://www.stantonlab.info Education Princeton University BSE ...
As awareness about dementia continues to grow worldwide, a spate of online courses aims to help both health professionals and the general public understand Alzheimer’s and related diseases. Below is a ...
TASTPM is a double transgenic mouse model of Alzheimer’s disease carrying two mutations associated with early onset disease: the Swedish mutation in APP and the M146V mutation in PSEN1. The double ...
The following are selected lists of antibodies against microglial proteins that are available through the Monoclonal Antibody Core Facility at Helmholtz Munich.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results